Sybert V P
J Pediatr. 1984 Mar;104(3):365-9. doi: 10.1016/s0022-3476(84)81096-3.
Adult heights of 66 individuals with karyotype documentation of Turner syndrome were analyzed. The mean adult height of 29 individuals given growth-promoting hormones, oxandrolone or fluoxymesterone, did not differ significantly from that of 37 untreated subjects (148.1 +/- 4.7 vs 146.3 +/- 5.5 cm, respectively). The type of X chromosome abnormality did not influence the mean adult height. No significant deleterious effect on height was seen with earlier induction of puberty with estrogens. Parental heights did not appear to influence final adult height. Based on this study, the use of androgens to increase adult height in Turner syndrome cannot be recommended and there appears to be no benefit in delaying induction of puberty with exogenous hormones beyond the mid-teens (14 to 16 years).
对66例有核型记录的特纳综合征患者的成人身高进行了分析。给予生长促进激素、氧雄龙或氟甲睾酮的29例患者的平均成人身高与37例未治疗患者的平均成人身高相比无显著差异（分别为148.1±4.7厘米和146.3±5.5厘米）。X染色体异常的类型不影响平均成人身高。雌激素较早诱导青春期对身高未见明显有害影响。父母身高似乎不影响最终成人身高。基于这项研究，不建议使用雄激素来增加特纳综合征患者的成人身高，而且在青少年中期（14至16岁）之后使用外源激素延迟青春期诱导似乎没有益处。
